AstraZeneca Announced Enhertu Approved In China For Patients With Previously Treated HER2-Positive Advanced Or Metastatic Gastric Cancer
AstraZeneca Announced Enhertu Approved In China For Patients With Previously Treated HER2-Positive Advanced Or Metastatic Gastric Cancer
阿斯利康宣布恩赐图获批用于中国先前接受过治疗的HER2阳性晚期或转移性胃癌患者。
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has received conditional approval in China as a monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received two or more prior treatment regimens.
阿斯利康和第一三共的爱文思肝癌射（曲妥珠单抗-杂醇酸酯）获得中国条件批准，作为单药治疗，用于治疗局部晚期或转移性HER2阳性胃癌或胃食管连接处腺癌患者，这些患者已接受两个或两个以上的先前治疗方案。